NASEM to fund impaired driving research • Germany hosts global forum • Canada approves Epidiolex • & more …
An excerpt from recent editions of the Cannabis Wire Daily newsletter.
Mexico looks to US on cannabis taxes • Epidiolex sales boom • NJ Gov talks cannabis in State of the State • & more…
An excerpt from recent editions of the Cannabis Wire Daily newsletter.
FDA Approves Epidiolex for New Condition That Causes Benign Tumors, Seizures
Epidiolex contains cannabidiol, or CBD, extracted from cannabis plants, and was first approved to treat severe forms of epilepsy.
Epidiolex sales hit $188M • FreshDirect founder joins TerrAscend board • & more…
An excerpt from the November 5 and 6 editions of the Cannabis Wire Daily newsletter.
GOP Congress members ask DEA for “briefing” on illegal cannabis farms • Conn. AG calls out Eventbrite for listing unlicensed event • & more …
An excerpt from recent editions of the Cannabis Wire Daily newsletter.
UK gov’t remains “concerned” about adult use • South Africa’s adult use bill advances • What does the latest national drug use survey say about cannabis? • & more …
An excerpt from recent editions of the Cannabis Wire Daily newsletter.
FDA Looks Back On Fifty Years of Cannabis Research, Prepares for Growth Ahead
FDA researchers published an article this week titled “From Our Perspective: FDA’s 50 Years of Experience with Cannabis Research Helping to Support Tomorrow’s Cannabis Drug Development.”
Congress Picks Up the Baton from the FDA on CBD, Seeking Data
The unregulated hemp-derived cannabinoid marketplace has exploded since the 2018 Farm Bill descheduled hemp. The FDA has asked Congress to help with a “new regulatory pathway.”
As FDA Looks to Congress for CBD Regs, it Elaborates on Potential Paths Forward
On Thursday, the FDA pushed its desire to work with Congress on cannabinoid product rules, including delta-8 THC.